Title of article :
The dopamine–somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways
Author/Authors :
Paola and Peverelli، نويسنده , , Erika and Olgiati، نويسنده , , Luca and Locatelli، نويسنده , , Marco and Magni، نويسنده , , Paolo and Fustini، نويسنده , , Marco Faustini and Frank، نويسنده , , Giorgio and Mantovani، نويسنده , , Giovanna and Beck-Peccoz، نويسنده , , Paolo and Spada، نويسنده , , Anna and Lania، نويسنده , , Andrea، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2010
Pages :
7
From page :
170
To page :
176
Abstract :
The study investigated the effects of the dopamine-somatostatin chimeric compound BIM-23A760 on cell proliferation and apoptosis in cultured cells from human non-functioning pituitary tumors (NFPTs). Both BIM-23A760 and the dopaminergic agonist BIM-53097 induced a significant inhibition of cell proliferation associated with increased p27 expression, together with a significant increase in caspase-3 activity. Conversely, null or marginal effects were elicited by somatostatin analogs. Moreover, BIM-23A760 and BIM-53097 induced ERK1/2 and p38 phosphorylation and the blockade of these pathways prevented both the antiproliferative and the pro-apoptotic effects of these drugs. In conclusions the chimeric compound BIM-23A760 is able to exert cytostatic and cytotoxic effects in NFPTs, these phenomena being mainly mediated by DR2D and involving ERK1/2 and p38 pathways activation.
Keywords :
Somatostatin receptor , dopamine receptor , apoptosis , chimera , Pituitary Adenoma , Cell Proliferation
Journal title :
Cancer Letters
Serial Year :
2010
Journal title :
Cancer Letters
Record number :
1818227
Link To Document :
بازگشت